Drugs / ILB®
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03705390 | Mar 2019 → Jul 2021 | amyotrophic lateral sclerosis | University of Birmingham | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ILB | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03705390 ↗ |
| Modality | Other / unclassified | “a type of low molecular weight dextran sulfate” NCT03705390 ↗ |
| Route | Subcutaneous | “weekly subcutaneous injections” NCT03705390 ↗ |